首页> 外文期刊>Frontiers in Pharmacology >Analyses of mRNA Profiling through RNA Sequencing on a SAMP8 Mouse Model in Response to Ginsenoside Rg1 and Rb1 Treatment
【24h】

Analyses of mRNA Profiling through RNA Sequencing on a SAMP8 Mouse Model in Response to Ginsenoside Rg1 and Rb1 Treatment

机译:人参皂苷Rg1和Rb1处理对SAMP8小鼠模型的RNA测序通过RNA测序的mRNA分析。

获取原文
           

摘要

Ginsenoside Rg1 and Rb1 are the major ingredients in two medicines called QiShengLi (Z20027165) and QiShengJing (Z20027164) approved by China. These ingredients are believed to mitigate forgetfulness. Numerous studies have confirmed that GRg1 and GRb1 offer protection against Alzheimer's disease (AD), and our morris water maze (MWM) experiment also indicated that GRg1 and GRb1 may attenuate memory deficits in the 7-month-old SAMP8 mice; however, comprehensive understanding of their roles in AD remains limited. This study systematically explored the mechanism at the genome level of the anti-AD effects of GRg1 and GRb1 in a senescence-accelerated mouse prone 8 (SAMP8) model through deep RNA sequencing. A total of 74,885 mRNA transcripts were obtained. Expression analysis showed that 1,780 mRNA transcripts were differentially expressed in SAMP8 mice compared with the SAMP8+GRg1 mice. Moreover, 1,066 significantly dysregulated mRNA transcripts were identified between SAMP8 and SAMP8+GRb1 mice. Analyses according to gene ontology and the Kyoto Encyclopedia of Genes and Genomes revealed that oral administration of GRg1 and GRb1 improved the learning performance of the SAMP8 mouse model from various aspects, such as nervous system development and mitogen-activated protein kinase signaling pathway. The most probable AD-related transcriptional responses after medication were predicted and discussed in detail. This study is the first to provide a systematic dissection of mRNA profiling in SAMP8 mouse brain in response to GRg1 and GRb1 treatment. We explained their efficacy thoroughly from the source (gene-level explanation). The findings serve as a theoretical basis for the exploration of GRg1 and GRb1 as functional drugs with anti-AD activity.
机译:人参皂苷Rg1和Rb1是中国批准的两种药物中的主要成分,分别为QiShengLi(Z20027165)和QiShengJing(Z20027164)。据信这些成分减轻了健忘。大量研究证实,GRg1和GRb1可以抵抗阿尔茨海默氏病(AD),而我们的莫里斯水迷宫(MWM)实验也表明,GRg1和GRb1可以减轻7个月大的SAMP8小鼠的记忆缺陷。但是,对其在AD中的作用的全面了解仍然有限。这项研究通过深度RNA测序系统性地探索了基因组水平上的GRg1和GRb1在衰老加速的小鼠俯卧8(SAMP8)模型中的抗AD作用的机制。总共获得了74,885个mRNA转录本。表达分析表明,与SAMP8 + GRg1小鼠相比,在SAMP8小鼠中差异表达了1,780个mRNA转录本。此外,在SAMP8和SAMP8 + GRb1小鼠之间鉴定到1,066个明显失调的mRNA转录物。根据基因本体论和《京都基因与基因组百科全书》的分析,口服GRg1和GRb1可从神经系统发育和促有丝分裂原激活的蛋白激酶信号传导途径等多个方面改善SAMP8小鼠模型的学习性能。药物治疗后最可能的与AD相关的转录反应得到了预测和详细讨论。这项研究是第一个提供对SAMP8小鼠大脑中GRg1和GRb1治疗反应的mRNA谱分析的系统剖析。我们从源头全面解释了它们的功效(基因水平的解释)。该发现为探索具有抗AD活性的功能药物GRg1和GRb1提供了理论基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号